// App-Quantinova.ai

7501 : A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL).

Researchers

Presenter

  • Adrienne Alise Phillips

Principal Investigators

  • Paul Fields

  • Olivier Hermine

  • Juan Carlos Ramos

  • Brady Ernesto Beltran

  • Juliana Pereira

  • Carlos Brites

  • Michael R. Kurman

  • Joyce George

  • Karen M. Dwyer

  • Kevin Conlon

  • Graham P. Taylor

  • Jason Parker Gonsky

  • Steven M. Horwitz

Medical Centers

  • New York Presbyterian Weill Cornell Medical Center, New York, NY

  • Guy's Hospital, London, United Kingdom

  • Hospital Necker Service d'Hematologie, Paris, France

  • University of Miami/Sylvester Cancer Center, Miami, FL

  • Edgardo Rebagliati Martins Hospital, Surco, Peru

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil

  • Hospital Universitario Professor Edgar Santos, Salvador, Brazil

  • Kyowa Kirin Pharmaceuticals, Upper Saddle River, NJ

  • Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ

  • Kyowa Kirin Pharmaceuticals, Princeton, NJ

  • National Cancer Institute, Bethesda, MD

  • Imperial College, London, United Kingdom

  • State University of New York Downstate and Kings City Hospital Center, Brooklyn, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • Brazil

  • United Kingdom

  • United States

  • Peru

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Adult T-Cell Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Mogamulizumab

  • pralatrexate

Outcome

  • Positive

Study Design

  • Randomized

  • Cross Over

  • Double Blind/Blinded

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT01626664

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved